• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Antimicrob Chemother. NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases

Giuseppe

Emeritus
[Source: Journal of Antimicrobial Chemotherapy, full page: (LINK). Abstract, edited.]


NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases

Anu Jain 1, Katie L Hopkins 1, Jane Turton 1, Michel Doumith 1, Robert Hill 1, Richard Loy 1, Daniele Meunier 1, Rachel Pike 1, David M. Livermore 1,2 and Neil Woodford 1,*

Author Affiliations: <SUP>1</SUP>Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, Public Health England, London NW9 5EQ, UK <SUP>2</SUP>Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK

*Corresponding author. AMRHAI, PHE Reference Microbiology Services, 61 Colindale Avenue, London, NW9 5EQ, UK. Tel: +44 (0)20 8327 7255; E-mail: neil.woodford@phe.gov.uk

Received December 11, 2013. Revision requested January 28, 2014. Revision received March 4, 2014. Accepted March 6, 2014.


Abstract

Objectives

Gram-negative bacteria with diverse carbapenemases, including New Delhi metallo-β-lactamase (NDM) enzymes, have been increasingly recorded in the UK since 2007. We analysed patient data for NDM-positive isolates confirmed by the national reference laboratory from UK laboratories from February 2008 to July 2013.


Methods

Isolates resistant to carbapenems and with imipenem MICs reduced ≥8-fold by EDTA were tested by PCR for genes encoding acquired class B carbapenemases. MICs were determined by BSAC agar dilution methodology. When requested by the sender, or when they were members of apparent clusters, NDM-positive isolates were typed by variable number tandem repeat (VNTR) analysis or PFGE. Data provided by the sending laboratories were collated and reviewed.


Results

From February 2008 to July 2013 the reference laboratory confirmed 326 NDM-positive isolates from 250 patients, submitted by 83 laboratories. Most (85%, 213/250) patients were already hospitalized when the NDM-positive bacteria were detected, were male (61%, 152/250) and were aged >60 years (58%, 145/250). Travel history was available for only 40% of patients, but 52% (53/101) of these had documented healthcare contact within or travel to the Indian subcontinent. Most NDM-positive isolates (94%, 306/326) were Enterobacteriaceae with just 6% (20/326) non-fermenters; the predominant hosts were Klebsiella spp. (55%, 180/326) and Escherichia coli (25%, 80/326). Almost all NDM-positive isolates were resistant to multiple antibiotic classes, but 90% remained susceptible to colistin.


Conclusions

Gram-negative bacteria with NDM carbapenemases are a growing challenge, especially for elderly hospitalized patients, including those with healthcare contact in the Indian subcontinent, and leave few therapeutic options. UK outbreaks remain rare and contained.

Key words: MBLs ? meropenem ? Enterobacteriaceae ? Pseudomonas ? Acinetobacter


? Crown copyright 2014.

-
-------
 
Back
Top